Eli Lilly Chooses R/GA for Social Media Amid Weight-Loss Drug Surge

Eli Lilly's New Social Media Partner

Eli Lilly has appointed R/GA as its social media agency following a competitive pitch. This partnership will focus on promoting Zepbound, a GLP-1 weight-loss drug, along with other brands like Mounjaro. R/GA will not only manage social strategies but also assist in experience design for Eli Lilly.

FDA Approval Boosts Market Potential

In December, the U.S. FDA approved Eli Lilly's Zepbound for treating sleep apnea, marking a significant milestone as the first drug approved for this condition. This approval expands Eli Lilly's market, which has seen a surge in interest in weight-loss medications.

Industry Dynamics

R/GA's new role comes amidst its owner Interpublic Group's (IPG) potential sale, with IPG merging with rival Omnicom Group. Leaders from both companies have indicated that healthcare marketing will be a crucial growth area for their combined entity. The overall ad spending in healthcare and pharma in the U.S. is projected to exceed $30 billion by the end of 2024, reflecting a 5% year-over-year increase, according to eMarketer.

Conclusion

As R/GA steps into this significant role, it highlights the growing importance of innovative marketing strategies in the healthcare sector, especially in the wake of new drug approvals and market expansions.